Orig3n is a Boston-based biotech research company focused on genetics and regenerative medicine. It provides consumers access to genetic information to enable proactive, personalized health choices and conducts R&D into cell therapies. The company invests in cellular science to develop personalized therapies for repairing tissue damage and disease. Orig3n maintains a large allogeneic bank of cells that is HLA-matched to 90% of the U.S. population, which underpins its regenerative-medicine programs. It plans to use recent funding to expand domestically and internationally and to continue R&D to advance its regenerative treatments. As of the Series B, Orig3n has raised over $50 million since its 2014 founding. ORIG3N focuses on genetics and regenerative medicine, offering a line of direct-to-consumer genetic tests while advancing cellular science to develop personalized therapies. The company operates what it describes as a fully-matched allogeneic cell bank and is intensifying research into cell therapies. ORIG3N emphasizes community‑driven, patient-fueled research and cultivates engagement through events and educational initiatives. Management says the company is increasingly consumer-facing and aims to accelerate the future of regenerative medicine. ORIG3N was founded in 2014 and is positioning its research and community assets to support therapeutic development. Financially, the company has raised over $30 million in capital to date. Orig3n is a Boston, MA-based biotech company that develops a disease-modeling platform targeting rare and genetically inherited diseases using iPSC-derived differentiated cells. The company closed a $12.5m Series A financing to advance its programs. It will use the funds to launch LifeSystems™ cellular models created from its LifeCapsule™ bio-repository. Orig3n launched the LifeCapsule bio-repository, a living database and large bank of induced pluripotent stem cells to which anyone can contribute. The platform is intended to advance screening projects and deliver data to inform therapeutic decisions, aiming to replace trial-and-error approaches to treating disease. Orig3n was founded in 2014 by Robin Y. Smith. ORIG3N, based in Boston, MA, is developing a disease-modeling platform targeting rare genetically inherited diseases. Led by CEO and co-founder Robin Y. Smith, the company’s core product is the Life Capsule™, a bio-repository open to public contribution. The Life Capsule collects a small amount of blood and reprograms cells into induced pluripotent stem cells (iPSCs). These iPSCs are used for disease modeling outside the body to support critical medical research and potential individualized therapy. The company intends to use the newly raised funds to expand its Life Capsule offering. ORIG3N recently raised $3.1M in funding from institutional backers.

Total raised

$36M

Funding rounds

4

Latest round

Equity

Latest activity

Jun 2017